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Edited by Thomas L. JamesAbstract We have reported that human protein disulﬁde
isomerase-related protein (hPDIR) has isomerase and chaperone
activities that are lower than those of the human protein disulﬁde
isomerase (hPDI), and that the b domain of hPDIR is critical for
its chaperone activity [J. Biol. Chem. 279 (2004) 4604]. To
investigate the basis of the diﬀerences between hPDI and
hPDIR, and to determine the functions of each hPDIR domain
in detail, we constructed several hPDIR domain mutants.
Interestingly, when the b domain of hPDIR was replaced with
the b0 domain of hPDI, a dramatic increase in chaperone activity
that was close to that of hPDI itself was observed. However, this
mutant showed decreased oxidative refolding of a1-antitrypsin.
The replacement of the b domain of hPDIR with the c domain of
hPDI also increased its chaperone activity. These observations
suggest that putative peptide-binding sites of hPDI determine
both its chaperone activity and its substrate speciﬁcity.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein disulﬁde isomerase (PDI) catalyzes the oxidation,
reduction, and isomerization of protein disulﬁde bonds [1]. It is
believed to accelerate the folding of disulﬁde-bonded proteins
by catalyzing the disulﬁde interchange reaction, which is the
rate-limiting step of protein folding that occurs within the lu-
minal space of the endoplasmic reticulum (ER) [2–4]. PDI has
two distinct regions that contain the Cys–Gly–His–Cys
(CGHC) sequence. This sequence is similar to a motif found in* Corresponding author. Present address: Kobayashi Pharmaceutical
Co., Ltd., R&D Company, 30-3, 1-Chome, Toyokawa, Ibaraki-Shi,
Osaka 567-0057, Japan. Fax: +81-77-561-2659.
E-mail address: kikuchi@se.ritsumei.ac.jp (M. Kikuchi).
Abbreviations: hPDI, human protein disulﬁde isomerase; hPDIR,
human protein disulﬁde isomerase-related protein; ER, endoplasmic
reticulum; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel
electorophoresis; GSH, glutathione (reduced form); GSSG, glutathi-
one (oxidized form)
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doi:10.1016/j.febslet.2004.03.103thioredoxin, namely, Cys–Gly–Pro–Cys (CGPC), which is also
called the TX motif or CXXC motif. The CGHC sequences
serve as the active sites in PDI for thiol-disulﬁde bond ex-
change reactions [5]. In addition to catalyzing protein folding,
PDI functions as a b-subunit of prolyl 4-hydroxylase [6] and as
a component of triglyceride transfer protein [7]. It is also es-
sential for yeast viability [8–10]. Moreover, it has recently been
reported that PDI binds several drugs such as aminoglycoside
antibiotics [11,12] and copper [13], and that PDI is a major
calcium-binding protein in the ER [14,15]. However, the de-
tailed physiological roles that are played by these multiple
cellular functions of PDI still remain to be elucidated.
We recently reported that human protein disulﬁde isomer-
ase-related protein (hPDIR), which has three CXXC motifs,
namely, Cys–Ser–Met–Cys (CSMC), CGHC, and Cys–Pro–
His–Cys (CPHC), also has isomerase and chaperone activities,
although both activities were about 2% and 50% of those of
human protein disulﬁde isomerase (hPDI) [16]. We also
showed that hPDIR bears an oxidative refolding activity that
is speciﬁc for a1-antitrypsin [16].
hPDI and hPDIR have been proposed to bear the a–b–b0–
a0–c and b–a0–a–a0 domain structures, respectively [17]. The a0,
a, and a0 regions are redox-active thioredoxin domains, while b
and b0 are redox-inactive thioredoxin domains, and c is a
highly acidic region. Two of the CGHC sequences of PDI are
located in the a and a0 domains, while the CXXC motifs of
hPDIR are in the a0, a, and a0 domains [17]. A candidate
peptide-binding site is located in the b0 and c domains of PDI
[17], and little overall amino acid homology between hPDI and
hPDIR is observed. We found previously that the b domain of
hPDIR is crucial for its chaperone activity but not for its
isomerase activity, and that the chaperone activity of wild-type
hPDIR is approximately 50% that of the wild-type hPDI [16].
Here, we show that the replacement of the b domain of
hPDIR with the b0 domain of hPDI dramatically increases its
chaperone activity. The functions of each domain of hPDIR
and hPDI are also discussed.2. Materials and methods
2.1. Materials
Rhodanese, human a1-antitrypsin and N -succinyl–Ala–Ala–Pro–
Phe-p-nitroanilide were purchased from Sigma Chemical Co. (St.blished by Elsevier B.V. All rights reserved.
Fig. 1. The domain structure of wild type hPDIR and the hPDIR
domain mutants used in this study.
312 T. Horibe et al. / FEBS Letters 566 (2004) 311–315Louis, USA). A Hitrap SP FPLC column was purchased from
Amersham Biosciences (Uppsala, Sweden). a-Chymotrypsin and other
reagents were mostly obtained from Wako Pure Chemical Industries
(Osaka, Japan). All reagents were of research grade quality.
2.2. Strains and plasmids
Escherichia coli AD494 (DE3) {Dara, leu 7697, DlacX74, DphoA,
PvuII, PhoR, DmalF3, F
0
[lac, (lacIq), pro], trxB::kan (DE3)} and
pET-15b (Novagen, Inc., Madison, USA) were used to express
hPDIR, hPDI, and the hPDIR domain mutants.
2.3. Expression and puriﬁcation of hPDIR, hPDI, and domain mutants
of hPDIR
Expression plasmids encoding hPDIR, hPDI, and hPDIR domain
mutants were constructed using pET-15b according to the methods
described previously [16,18]. The expression and the puriﬁcation of
these proteins using a Ni2þ-chelating resin column were also performed
as described previously [16,18]. The proteins were puriﬁed further with
a Hitrap SP FPLC column after dialysis against 20 mM sodium
phosphate buﬀer (pH 7.12), and the proteins were eluted with a linear
gradient of 0–1 M NaCl. The purity of the proteins was determined by
sodium dodecyl sulfate–polyacrylamide gel electorophoresis (SDS–
PAGE), which was performed according to the method of Laemmli
[19]. The protein concentration was quantiﬁed using UV absorption
method [20].
2.4. Assays of the activities of hPDIR, hPDI, and hPDIR domain
mutants
Isomerase activity was determined according to the method of
Lambert and Freedman [21]. This method is based on the GSH-cata-
lyzed reduction of the disulﬁde bonds in insulin that is associated with
the reduction of GSSG to GSH, which is mediated by NADPH and
glutathione reductase. To discriminate between isomerase and chap-
erone activities, rhodanese, which does not contain disulﬁde bonds,
was used as a substrate for chaperone activity. Chaperone activity was
evidenced by the prevention of denatured rhodanese aggregation and
was assayed according to the methods of Martin et al. [22]. The oxi-
dative refolding of a1-antitrypsin was determined as described previ-
ously [16]. In all experiments, puriﬁed wild type hPDIR and hPDI were
used as controls.
2.5. Measuring the intrinsic ﬂuorescence emission spectra of hPDIR,
hPDI, and hPDIR domain mutants
Fluorescence spectra were collected on a Hitachi Spectroﬂuorometer
F-4010 using a 3 ml cuvette. All scans were collected at 25 C as an
average of three scans with excitation of 280 nm, emission of 300–400
nm, slit widths of 5 nm, and scan speed of 50 nm/min. All spectra were
corrected for the blank spectra with no protein added.
2.6. Secondary structure prediction
The amino acid sequences of the hPDIR b domain (2–115), the
hPDI b domain (118–217), and the hPDI b0 domain (218–351) were
analyzed by several diﬀerent algorithms on a protein secondary pre-
diction server. One algorithm, SSTHREAD (http://www.ddbj.nig.
ac.jp/E-mail/ssthread/welcome.html), yielded a secondary structure of
the hPDI b domain that ﬁtted particularly well to the secondary
structure that had been determined by nuclear magnetic resonance
(NMR) analysis [23,24]. This algorithm was selected for multiple
sequence alignment of the hPDIR b, hPDI b and b0 domains.Fig. 2. SDS–PAGE analysis of the hPDIR mutant proteins after their
puriﬁcation by Ni2þ-chelating resin column chromatography. Elec-
trophoresis was performed using 15% gels (see Section 2). Lane 1:
hPDIR-wild; lane 2: hPDIR-ba0; lane 3: hPDIR-a0a; lane 4: hPDR-
aa0; lane 5: hPDIb0/hPDIRa0aa0; lane 6: hPDIc/hPDIRa0aa0. The
numbers to the left indicate the sizes of the molecular weight markers.3. Results
3.1. Expression and puriﬁcation of wild type and domain
mutants of hPDIR
To understand the functional roles that are played by the
four domains of hPDIR, several hPDIR domain mutant
cDNAs were prepared by PCR [25]. The sequences of all
cDNAs were conﬁrmed by nucleotide sequence determination
(primers not shown). Fig. 1 shows the domain structure of the
wild type hPDIR protein and the domain mutants that were
used in this study. E. coli cells bearing expression plasmids
encoding these mutants were cultured as described in Section2, harvested, disrupted, and the supernatant was applied onto
a Ni2þ-chelating resin column. The resulting isolated pro-
teins were puriﬁed further by using a Hitrap SP FPLC column.
All puriﬁed proteins appeared as a single band after SDS–
PAGE (Fig. 2; the data for hPDIR-b, hPDIR-a0, hPDIR-a,
hPDIR-a0, hPDIR-ba0a, and hPDIR-a0aa0 have been shown
previously [16]).
3.2. Isomerase, oxidative refolding, and chaperone activities of
wild type hPDIR and domain mutants
As shown in Table 1, the individual domains of hPDIR did
not bear signiﬁcant isomerase activity apart from the a domain
(about 48% of the wild-type activity). The domain deletants
ba0, a0a, and aa0 showed about 25%, 78%, and 83% activity,
respectively. Notably, these activities were largely equivalent,
respectively, to the activities of the hPDIR-m23, hPDIR-m1,
and hPDIR m3 mutants that we examined in a previous study
[16]. These mutants lack one or two of the three CXXC active
sites in hPDIR due to the replacement of the cysteines with
Table 1
Activities of isomerase, chaperone, and oxidative refolding of wild and mutant hPDIR proteins
Protein CXXC motif % of wild hPDIR activity
Isomerase activity Oxidative refolding Chaperone activity
hPDm-wild –CSMC–CGHC–CPHC– 100.00 100.00 100.00
b N.D. 21.97 43.89
a0 –CSMC– 9.17 1.09 N.D.
a –CGHC– 47.72 1.66 N.D.
a0 –CPHC– 11.36 1.67 N.D.
ba0 –CSMC– 25.14 81.29 50.00
m23 –CSMC–SGHS–SPHS– 24.35 89.73 101.33
a0a –CSMC–CGHC– 78.15 1.81 N.D.
m3 –CSMC–CGHC–SPHS– 68.83 93.94 101.16
aa0 –CGHC–CPHC– 83.25 2.42 N.D.
m1 –SSMS–CGHC–CPHC– 82.23 67.18 100.11
a0aa0 –CSMC–CGHC–CPHC– 96.82 9.68 N.D.
ba0a –CSMC–CGHC– 65.92 93.05 98.84
hPDIb0/hPDIRa0aa0 –CSMC–CGHC–CPHC– 73.18 10.08 186.24
hPDIc/hPDIRa0aa0 –CSMC–CGHC–CPHC– 101.03 9.67 155.54
The chaperone activity was examined using rhodanese as a substrate. The value of the activity of the wild type hPDIR was set to 100%. Underlined
residues indicate cysteine residues that were replaced with serine as described previously [16]. Values for the mutants m23, m3, and m1 were derived
from previous data [16]. Each value is shown as the mean of two separate experiments. N.D. indicates not detected.
T. Horibe et al. / FEBS Letters 566 (2004) 311–315 313serine as shown in Table 1. Thus, the m1 and m3 mutants have
an inactivated SXXS in their a0 or a0 domain, respectively,
while the a and a0 domains in the m23 mutant both bear an
inactivated SXXS. These observations indicate that the pres-
ence of only one domain bearing a CXXC motif cannot fully
exert the isomerase activity of the protein and that at least two
CXXC-bearing domains are required for this activity.
With regard to the ability of hPDIR to oxidatively refold a1-
antitrypsin and to serve as a chaperone, the domain deletants
a0, a, a0, a0a, and aa0 were almost completely inactive (Table
1). In contrast, the oxidative refolding activities of the domain
deletants b, ba0, and ba0a were about 22%, 81%, and 93% of
the wild type activity, while their chaperone activities were
about 44%, 50%, and 99%, respectively (Table 1). These ob-
servations are consistent with our previous report that showed
that the hPDIR mutant that lacks the b domain has poor
peptide-binding, chaperone, and a1-antitrypsin oxidative re-
folding abilities [16]. These observations together indicate that
the b domain of hPDIR is critical for binding to its substrates
and exerting its chaperone activity, while the a0, a, and a0
domains (at least two of the three) are needed for isomerase
activity.
3.3. Isomerase, oxidative refolding, and chaperone activities of
hPDIR mutants whose b domain has been replaced with the
b0 or c domains of hPDI
The isomerase activity of hPDIR is much lower than that of
hPDI, while its chaperone activity is about 50% of that of
hPDI [16]. To determine the basis of these activity diﬀerences
between hPDI and hPDIR, we constructed hPDIR/hPDI do-
main chimeras in which the b domain of hPDIR has been
replaced with the b0 or c domains of hPDI. These mutants were
designated hPDIb0/hPDIa0aa0 and hPDIc/hPDIRa0aa0, re-
spectively. Interestingly, hPDIb0/hPDIa0aa0 showed a dramatic
increase in chaperone activity compared to wild type hPDIR
(about 186%), while hPDIc/hPDIRa0aa0 also showed an in-
creased activity (about 156%) (Table 1). Their isomerase ac-
tivities did not increase similarly, as they were about 73% and
101% of that of wild type hPDIR, respectively (Table 1).
However, their a1-antitrypsin oxidative refolding abilities weremuch lower than that of wild type hPDIR (about 10% and 9%,
respectively) (Table 1). BIACORE analysis showed that
hPDIb0/hPDIRa0aa0 and hPDIc/hPDIRa0aa0 can interact with
mastoparan with KD values of 5.81 105 and 5.51 105 M,
respectively (data not shown). These values are almost equiv-
alent to those of wild-type hPDI (3.46 105 M) [16,18] and
hPDIR (4.67 105M) [16]. These observations indicate that
the b domain of hPDIR is critical for its substrate speciﬁcity,
particularly for the oxidative refolding of a1-antitrypsin, and
that the role of the b0 and c domains of hPDI is deﬁnite for the
chaperone activity.
3.4. Intrinsic ﬂuorescence emission spectra of hPDIR, hPDI,
hPDIb0/hPDIRa0aa0, and hPDIc/hPDIRa0aa0
The increased chaperone activity of hPDIb0/hPDIRa0aa0
and hPDIc/hPDIRa0aa0 prompted us to analyze these mutants
biophysically. As shown in Fig. 3, hPDIb0/hPDIRa0aa0 and
hPDIc/hPDIRa0aa0 are well structured. The hPDIR, hPDI,
hPDIb0/hPDIRa0aa0, and hPDIc/hPDIRa0aa0 proteins all
showed a kmax of 335 nm in the ﬂuorescence spectra. However,
their intensities diﬀered (Fig. 3). Interestingly, the hPDIb0/
hPDIRa0aa0 and hPDI-wild spectra were almost identical,
unlike those of hPDIR and hPDIc/hPDIRa0aa0 (Fig. 3). This
indicates that the overall structures of hPDIb0/hPDIRa0aa0
and hPDI resemble each other and that replacing the hPDIR b
domain with the hPDI b0 or c domains aﬀects the three-
dimensional structure of hPDIR.
3.5. Prediction of the secondary structures of the hPDIR b,
hPDI b, and hPDI b0 domains
We subjected the hPDIR b, hPDI b, and hPDI b0 domains to
secondary structure prediction and multiple sequence align-
ment. The hPDIR b domain showed 10.52% and 12.28%
amino acid sequence similarity to those of the hPDI b and
hPDI b0 domains, respectively. Nevertheless, as shown in
Fig. 4, the hPDIR b domain has a similar secondary structure
to those of the hPDI b and b0 domains, which consist of an a=b
fold with the order of the elements of the secondary structure
being b1 (‘‘s’’ in Fig. 4), a1 (‘‘H’’), b2 (s), a2 (H), b3 (s), a3 (H),
b4 (s), and a4 (H), although the hPDIR b domain does not
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Fig. 3. Intrinsic ﬂuorescence of hPDIR, hPDI, and the hPDIR/hPDI
domain chimeras. Shown are the ﬂuorescence spectra of hPDIR,
hPDI, hPDIb0/hPDIRa0aa0, and hPDIc/hPDIRa0aa0. All spectra
shown are an average of three scans.
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hPDIR b domain also bears a thioredoxin-like fold, as do the a
and b domains of hPDI [23,24].4. Discussion
We previously reported that hPDIR has isomerase and
chaperone activities, although both activities were about 2%
and 50% of those of hPDI [16]. We also reported that the three
CXXC motifs of hPDIR play diﬀerent roles in mediating the
redox activity of the protein [16]. Although the isomerase ac-
tivity of hPDIR is much lower than that of hPDI, hPDIR
reactivated a1-antitrypsin more eﬀectively compared with
hPDI and hP5 [16]. These observations suggest that a1-anti-
trypsin is one of the speciﬁc substrates of hPDIR for catalyzingFig. 4. Secondary structure analysis of the b domain of hPDIR. Of the variou
Section 2, the SSTHREAD algorithm, which employs threading, yielded a se
structure that had been determined by NMR [23,24]. This program was used t
hPDIR b: human PDIR b domain (2–115); hPDI b: human PDI b domain (11
helix and sheet regions, respectively.disulﬁde bond formation in the ER lumen. In this study, to
elucidate the roles played by the individual domains of hPDIR
in more detail, we constructed several hPDIR domain dele-
tants. Analysis of these mutants revealed that the domain
deletants ba0, a0a, and aa0, which are constituted of two suc-
cessive domains, had almost the same respective isomerase
activity as the mutants hPDIR-m23, hPDIR-m1, and hPDIR
m3 (Table 1). These results indicate that at least two successive
domains bearing a CXXC motif are necessary for exerting the
isomerase activity of hPDIR. Moreover, while the domain
deletants a0, a, a0, a0a, and aa0 lack chaperone and a1-anti-
trypsin oxidative refolding activities, the chaperone activities
of b, ba0, and ba0a were about 44%, 50%, and 99% of wild type
hPDIR activity, respectively (Table 1). Furthermore, their a1-
antitrypsin oxidative refolding activities were about 22%, 81%,
and 93%, respectively (Table 1). All single domains b, a0, a,
and a0 were expressed in a soluble form in E. coli, and puriﬁed
to homogeneity. Thus, there was no necessity for refolding.
The single domains a0, a, and a0 exerted isomerase activity, but
did not exert oxidative refolding and chaperone activities. On
the contrary, the domain b exerted oxidative refolding and
chaperone activities, but did not exert isomerase activity.
These observations are consistent with our previous report
that showed that the hPDIR mutant that lacks the b domain
has poor peptide-binding, chaperone, and a1-antitrypsin oxi-
dative refolding activities [16]. Thus, the b domain of hPDIR is
critical for its chaperone activity.
While the b domain of hPDIR is needed for both its chap-
erone activity and its substrate speciﬁcity, the chaperone ac-
tivity of this protein is lower than that of hPDI [16]. To
investigate the basis of these diﬀerences between hPDI and
hPDIR, we constructed the hPDIb0/hPDIa0aa0 and hPDIc/
hPDIRa0aa0mutants, since it has been reported that the b0 and
c domains of hPDI are critical for its peptide-binding and
chaperone activities [26,27]. Interestingly, as shown in Table 1,
the chaperone activity of hPDIb0/hPDIRa0aa0 was dramati-
cally higher than that of the wild-type protein (about 186% of
wild-type activity), which is almost equivalent to that of hPDIs protein secondary prediction programs that we tested as described in
condary structure of the b0 domain of hPDI that ﬁtted the best to the
o analyze the secondary structures of the hPDIR and hPDI b0 domains.
8–217); hPDI b0: human PDI b0 domain (218–351). H and s indicate the
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mutant also showed increased chaperone activity (about 156%
of wild-type activity) (Table 1). However, the a1-antitrypsin
oxidative refolding activities of both chimeric mutants are
much lower than that of wild-type hPDIR (Table 1). These
results suggest that both the b0 and c domains of hPDI are
critical for exerting the chaperone activity and substrate
speciﬁcity of this protein.
As shown in Fig. 3, the hPDIb0/hPDIRa0aa0 and hPDIc/
hPDIRa0aa0 mutants diﬀer structurally from wild-type
hPDIR. Interestingly, intrinsic ﬂuorescence spectra showed
that hPDIb0/hPDIRa0aa0 structurally resembles wild-type
hPDI more than wild-type hPDIR (Fig. 3). This suggests that
the structural changes of hPDIR caused by substituting its b
domain with the hPDI b0 domain are responsible for its in-
creased chaperone activity. Mastoparan is composed of 14
amino acids and has been reported to bind to hPDI [28] and
hPDIR [16]. Despite the structural changes caused by replac-
ing the b domain of hPDIR, BIACORE analysis showed that
hPDIb0/hPDIRa0aa0 and hPDIc/hPDIRa0aa0 can interact with
mastoparan with KD values of 5.81 105 and 5.51 105 M,
respectively (data not shown). These values are almost equiv-
alent to that of wild-type hPDI (3.46 105 M) [16,18] and
hPDIR (4.67 105 M) [16]. These observations strongly
support the notion that the hPDIR b domain and the hPDI b0
and c domains are critical for both the presence and the
strength of chaperone activity.
We next subjected the b domain of hPDIR to secondary
structure prediction analysis and multiple sequence alignment
with the sequences of the hPDI b and b0 domains (Fig. 4).
Several programs that predicted secondary structures were
tested. The one that yielded a structure that best ﬁtted the
structure of the hPDI b domain that was determined by NMR
was SSTHREAD [23,24]. This program was selected for the
multiple sequence alignment. As shown in Fig. 4, the b domain
of hPDIR seems to be structurally similar to the b0 and b
domains of hPDI and to bear a thioredoxin-like fold. Ke-
mmink et al. have analyzed the three-dimensional structures of
the a and b domains of hPDI by NMR and thereby showed
that hPDI consists of active and inactive thioredoxin-like folds
[23]. Although the b domain of hPDI is thioredoxin-inactive,
the three-dimensional structure of this domain resembles that
of the a domain of hPDI, which has a thioredoxin-like fold
[23,24]. Moreover, Pirneskoski et al. [29] recently reported that
the b0 domain of hPDI also bears a thioredoxin-like fold by
using secondary structural prediction and homology modeling.
They also reported that the b0 domain of hPDI contains the
linker region at its C-terminus, which forms an unaligned ex-
tension of the aligned thioredoxin-like section, and designated
this region as x region. As shown in Fig. 4, it is suggested that
the b domain of hPDIR does not contain the x region. These
observations strongly support the notion that, despite the very
low level of amino acid sequence similarity of the b domain of
hPDIR to the b0 domain of hPDI, this domain also bears a
thioredoxin-like fold. However, the b domain of hPDIR does
not have a b5 (s) unlike the b domain of hPDI. It is known that
the b0 and c domains of hPDI are necessary for the peptide-
binding activity of this protein [26,27], and that the b domain
of hPDIR determines the substrate speciﬁcity of its oxidative
refolding activity [16]. This, together with the high level of
structural similarity between the hPDIR b domain and thehPDI b0 domain, suggests that these domains are able to dis-
criminate between speciﬁc substrates. Pirneskoski et al. [29]
also reported that the I272 residue in the b0 domain of hPDI is
critical for its peptide-binding activity. Our results thus suggest
that the b domain of hPDIR may also contain particular
amino acids that direct its substrate speciﬁcity.
We are currently seeking to identify the critical sites in the b
domain of hPDIR that mediates its peptide-binding and sub-
strate speciﬁcity by introducing various amino acid mutations.References
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